STOCK TITAN

Intellia Therape SEC Filings

NTLA NASDAQ

Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

CRISPR breakthroughs are exciting—decoding the filings that fund them is not. Intellia Therapeutics’ reports weave gene-editing science, FDA guidance and collaboration accounting into 200-plus pages that overwhelm even seasoned analysts. Whether you’re hunting for "Intellia Therapeutics insider trading Form 4 transactions" before a clinical read-out or trying to spot fresh IP claims, the detail can feel impenetrable.

Stock Titan solves that problem. Our AI reads every "Intellia Therapeutics quarterly earnings report 10-Q filing" the moment it hits EDGAR, flags pivotal pipeline updates, and links R&D spend to trial timelines. Need "Intellia Therapeutics Form 4 insider transactions real-time"? We stream those alerts alongside plain-English context so you can judge sentiment swiftly. Our platform turns "Intellia Therapeutics SEC filings explained simply" from hope to reality by pairing side-by-side summaries with source paragraphs.

Use the page to:

  • Compare cash runway and dilution scenarios with "Intellia Therapeutics earnings report filing analysis".
  • Skim risk-factor changes in "Intellia Therapeutics annual report 10-K simplified" without scrolling endlessly.
  • Track board pay packages via "Intellia Therapeutics proxy statement executive compensation" and assess alignment.
  • Monitor "Intellia Therapeutics 8-K material events explained" for trial halts, collaborations, or FDA designations.
  • Follow "Intellia Therapeutics executive stock transactions Form 4" to spot confidence shifts ahead of data.
  • Accelerate due diligence by "understanding Intellia Therapeutics SEC documents with AI" instead of manual parsing.

Every filing—10-K, 10-Q, 8-K, Form 4, S-3, DEF 14A and more—updates in real time, wrapped in concise AI-powered insights. Spend minutes, not days, extracting the gene-editing intelligence that drives your next decision.

Rhea-AI Summary

Intellia Therapeutics, Inc. (NTLA) – Form 4 insider transaction

EVP & Chief Technical Officer Eliana Clark reported the sale of 1,022 common shares on 01 July 2025 at a price of $9.82 per share (transaction code “S”). The shares had been purchased a day earlier under the company’s 2016 Employee Stock Purchase Plan and were therefore treated as non-derivative shares in Table I.

Following the disposition, Clark’s direct beneficial ownership stands at 95,369 shares. No derivative securities transactions were reported in Table II, and no Rule 10b5-1 trading plan box was checked, indicating the sale was executed outside of a pre-arranged trading program.

The filing represents a 1.1 % reduction in Clark’s directly held position (1,022 / 96,391 pre-sale) and is relatively small in dollar terms (~$10,000). No other insiders are included in this filing, and there is no indication of broader strategic implications for NTLA. Investors typically monitor insider activity for sentiment signals; however, a sale of this size by one executive is generally viewed as routine portfolio management rather than a material change in outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.

The dollar value of the sale (≈ $25 k) is immaterial relative to Intellia’s market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock’s fundamental outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Form 4 filing overview: On 07/02/2025, Chief Executive Officer Michael Heltzen reported an open-market purchase (transaction code “P”) of 1,040 shares of Exozymes Inc. (ticker EXOZ) common stock at a price of $10.22 per share. Following the transaction, Heltzen’s direct beneficial ownership increased to 10,628.8 shares. No derivative securities transactions were reported, and the filing was submitted individually (not jointly).

The purchase represents a modest addition to the CEO’s holdings and is the earliest reportable transaction for the period. Because the form lists no sales or derivative exercises, it signals a net increase in insider ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.

  • 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
  • 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
  • After the grant, Keresty directly owns 31,883 common shares.

No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Intellia Therape (NTLA)?

The current stock price of Intellia Therape (NTLA) is $11.535 as of July 11, 2025.

What is the market cap of Intellia Therape (NTLA)?

The market cap of Intellia Therape (NTLA) is approximately 1.1B.

What is the primary focus of Intellia Therapeutics?

Intellia Therapeutics focuses on developing curative medicines using CRISPR/Cas9 gene editing technology to precisely alter disease-causing genes in both in vivo and ex vivo settings.

How does Intellia Therapeutics generate its revenue?

The company operates through strategic clinical development and research, leveraging collaborations and licensing agreements while advancing a comprehensive pipeline of gene editing therapies.

What types of diseases is Intellia targeting with its therapies?

Intellia’s therapeutic pipeline targets genetically defined diseases such as hereditary angioedema, ATTR amyloidosis, and other conditions where gene editing can offer a transformative treatment approach.

What makes Intellia’s technology unique?

Intellia employs CRISPR/Cas9-based platforms that allow for precise editing of genetic sequences with unparalleled flexibility, backed by a strong intellectual property portfolio and advanced delivery methods.

How does Intellia ensure the safety and efficacy of its therapies?

The company implements rigorous clinical trial protocols, adheres to strict regulatory standards, and adopts comprehensive safety monitoring to ensure that all therapies meet high standards of efficacy and safety.

Can you explain Intellia’s business model?

Intellia’s business model integrates innovative research with strategic clinical development, leveraging robust collaborations and a diverse pipeline to advance novel, potentially curative gene editing therapies.

What role do strategic collaborations play at Intellia?

Collaborations with established industry partners provide access to complementary expertise, accelerate research timelines, and support the advancement of clinical trials, thereby strengthening Intellia’s market position.

How is the company positioned within the gene editing industry?

Intellia is recognized for its deep scientific expertise, a strong IP portfolio, and a well-developed clinical pipeline, positioning it as a key innovator in the rapidly evolving field of CRISPR-based therapeutics.
Intellia Therape

NASDAQ:NTLA

NTLA Rankings

NTLA Stock Data

1.11B
98.09M
5.05%
91.72%
25.15%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CAMBRIDGE